Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study.
Zinzani PL, Trněný M, Ribrag V, Zilioli VR, Walewski J, Christensen JH, Delwail V, Rodriguez G, Venugopal P, Coleman M, Dartigeas C, Patti C, Pane F, Jurczak W, Taszner M, Paneesha S, Zheng F, DeMarini DJ, Jiang W, Gilmartin A, Mehta A.
Zinzani PL, et al. Among authors: gilmartin a.
EClinicalMedicine. 2023 Aug 10;62:102131. doi: 10.1016/j.eclinm.2023.102131. eCollection 2023 Aug.
EClinicalMedicine. 2023.
PMID: 37599908
Free PMC article.